soul trial oral semaglutide cardiovascular outcomes 2024 Effects of on in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized Oral Semaglutide and Cardiovascular Outcomes
Pay in 4 interest-free payments of $5.02 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14











:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)

















